US FDA's "Bad Ad" programme puts scrutiny on sales reps' statements
This article was originally published in Scrip
Executive Summary
In a new programme signalling a more aggressive and expansive approach to regulating drug advertising, the US FDA is urging healthcare providers to report misleading promotional activities that occur in private settings, such as doctors' offices and seminars.